You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. High stretch, environmentally robust hybridsil, perfluoroelastomer barrier composits for CBRN protective ensembles

    SBC: Nanosonic Inc.            Topic: CBD181003

    Electro-optical infrared and long wavelength infrared detectors and sensors are increasingly important for the Chemical/Biological Defense community. Solid-state optical cooler materials are in demand for replacing mechanical closed cycle coolers used in current LWIR standoff sensors to achieve cryogenic temperatures. Recent advances in optical cooling of rare-earth doped materials are pointing to ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  2. Durable Stretch Barrier Materials

    SBC: Luna Innovations Incorporated            Topic: CBD181003

    The proliferation of weapons of mass destruction (WMDs) presents a serious security threat to U.S. and allied personnel around the world. Military personnel and first responders must be prepared to operate under a wide range of chemical, biological, radiological, nuclear (CBRN) threats. Commercially available CBRN protective suits are bulky offering little dexterity to the wearer, therefore new st ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  3. Stable Formulation of Nerve Agent Intoxication Countermeasures

    SBC: Luna Innovations Incorporated            Topic: CBD181005

    In response to the defined need for minimizing the carry weight of combat teams while retaining capability, Luna Innovations is proposing the development of a stable formulation of atropine and scopolamine for use in an autoinjector to combat nerve agent intoxication. The combined formulation of atropine and scopolamine will allow for better treatment with more physiological coverage within the hu ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  4. Dual Formulation of Atropine/Scopolamine with Enhanced Stability

    SBC: Cmc Pharmaceuticals, Inc.            Topic: CBD181005

    CMC Pharmaceuticals, Inc. (Cleveland, OH) is proposing developing a stable, combination product of two small molecule drug candidates as a counter measure to chemical warfare nerve agents (NA). The combination product is expected to exploit complementary pharmacological profiles for optimal muscarinic receptor blockade and anticholinergic activity within the peripheral and central nervous system. ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  5. Field Portable Mass Spectrometry for Small Molecule Drugs in Clinical Samples

    SBC: Spectral Energies, LLC            Topic: CBD181006

    We propose a novel two-dimensional mass spectrometry (2D-MS) technique based on ion trap arrays to identify illicit and designer drugs. This approach will give an unprecedented multiplex advantage for miniature mass spectrometry, allowing novice field technicians to rapidly identify drugs affecting the central nervous system based on both the m/z ratio and fragmentation pattern of an ion. Towards ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  6. Bi-specific Antibodies Targeting Disease Caused by Encephalitic Alphaviruses

    SBC: BRHMS LLC            Topic: CBD181007

    Highly pathogenic alphaviruses like VEEV/EEV/WWEEV cause encephalitis in humans and equids. These infections are endemic in wide regions of the developing world. Translational research regarding these pathogens is focused on developing new strategies to detect, treat and ideally protect humans and animals from these infections. Gene-encoded antibodies against alphavirus E1/E2 surface proteins will ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  7. Cervical Spine Health Improvement Products

    SBC: Switchbox, Inc.            Topic: DHA18B001

    Most standard-of-care tools and techniques for evaluating neck disorders are subjective, unreliable, and do not provide actionable information for providers, payers, and organizations to deliver efficient and effective care. This lack of objective neck he

    STTR Phase I 2019 Department of DefenseDefense Health Agency
  8. Augmented Reality Surgical Visualization

    SBC: CFD Research Corporation            Topic: DHA191001

    Care for the wounded Warfighters in austere and remote settings makes medical knowledge, skills and efficiency of the military medical professional paramount. For wounds that extend deep into internal anatomy, proper visualization of internal anatomy can

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
  9. Advanced Simulated Patient Intelligent Response Engine (ASPIRE)

    SBC: Vcom3D, Inc.            Topic: DHA191002

    The goal of medical simulation-based training such as high-fidelity manikin simulators, part task trainers, and screen-based virtual patients, is to approximate real-life treatment experiences without risk to live patients. While the use of sensors has ma

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
  10. Intelligent Patient Simulation Platform

    SBC: Sharp Vision Software LLC            Topic: DHA191002

    A proof-of-concept research on Intelligent Patient Platform is proposed with the goal to improve healthcare training experience by adding natural language capability to patient simulators by leveraging the latest artificial intelligent technologies so tha

    SBIR Phase I 2019 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government